Navigation Links
The Number of Biotechnology Companies has Only Decreased by 10% Despite the Crisis

The Number of Biotechnology Companies has Only Decreased by 10% Despite the... -- PAMPLONA, Spain, September 30, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Surveys, Polls and Research Click to view news release full screen  

The Number of Biotechnology Companies has Only Decreased by 10% Despite the Crisis


PAMPLONA, Spain, September 30, 2010 /PRNewswire/ -- The global biotechnology industry has been more resistant to the economic crisis than expected. This has been one of the main conclusions of the international round table "Opportunities and Challenges of the Global Biomarkets", held as part of the 5th International Meeting on Biotechnology, BioSpain 2010, organised by the Spanish Association of Biocompanies (ASEBIO) and the Government of Navarre through SODENA. During this event, experts from around the world have talked about their experience of each of their geographic locations in the field of biotechnology. Among the most important issues discussed they highlighted two: the increasing selectiveness of investors and the cuts in R&D+i. An important figure that was discussed was a "modest decrease" of 10% of the number of biotechnology companies worldwide, despite the crisis. During the round table it was made clear that "financing is the main problem faced by biotechnology today".

The Minister of Science and Innovation, Cristina Garmendia, has visited BioSpain 2010 to "see how Pamplona has become the nerve centre of European biotechnology". The Minister has mentioned the support offered by the central Government. "Undoubtedly, the biotechnology sector is bound to become one of the crucial sectors involved in our economic recovery, and I think that the figures and the international interest shown are proof of this; this helps us understand that it is the way forward". Garmendia referred to the General State Budgets, presented today, which allocate over 5.35 billion euros to the Ministry of Science and Innovation, 1.2 % more than the previous year. "With this budget, which has yet to be passed through parliament, we can guarantee the financing of all the contracts, grants, research projects and transfers of research to public bodies".

The protagonist of today's plenary session was Larry Fritz, president and CEO of Covella Pharmaceuticals, who stressed that the current model of venture capital has to be revised. "Venture capital has lost its entrepreneurial mindset; today investors leave their decisions in the hands of external consultants who, in many cases, are too critical of the projects that require financing". Larry Fritz, who focused his talk on how to create and develop a successful biotechnology company, insisted that investors are more conservative and that work is done more slowly than a few years ago.

More information: Lucia Cecilia Mercado +34-91-210-93-74

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
5. A number of European companies working together to create innovative facades with nanomaterials
6. Rapid Increase in the Number of Worldwide Nanotechnology Degree Programs
7. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
8. Random numbers game with quantum dice
9. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
10. Yongye Biotechnology International Retains CCG Investor Relations
11. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 at Melbourne ... on a worldwide tour including several North American tour dates. The Exhibition is ...
(Date:11/30/2015)... 2015  HUYA Bioscience International, the leader in accelerating ... innovations, today announced it has signed a Memorandum of ... foster collaboration between KDDF and HUYA with the ultimate ... products for the global market. ... new innovative preclinical and clinical stage compounds. The company ...
(Date:11/30/2015)... Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... independent director, and the Company welcomes Neil Woodford,s ... a recent anonymous internet report on NW Bio.  The ... Linda Powers stated, "We agree with Mr. ...
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
Breaking Biology News(10 mins):